Search

everythinglearnresearchcommunity

for

Search:↓

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

B cells can both help and hinder the body's defense against melanoma.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Immunotherapy can help treat severe alopecia areata.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

TPA is about 50 times more effective at promoting tumors than MZ.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Research on non-muscle invasive bladder cancer has increased, with the U.S. leading, and highlights effective treatments like BCG despite some side effects.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Basonuclin helps keratinocytes multiply and prevents them from fully maturing.